| Literature DB >> 27406031 |
Takeji Umemura1, Satoru Joshita1, Tomoo Yamazaki1, Michiharu Komatsu1, Yoshihiko Katsuyama2, Kaname Yoshizawa3, Eiji Tanaka1, Masao Ota4.
Abstract
Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are liver-specific autoimmune conditions that are characterized by chronic hepatic damage and often lead to cirrhosis and hepatic failure. Specifically, the protein tyrosine phosphatase N22 (PTPN22) gene encodes the lymphoid protein tyrosine phosphatase, which acts as a negative regulator of T-cell receptor signaling. A missense single nucleotide polymorphism (SNP) (rs2476601) in PTPN22 has been linked to numerous autoimmune diseases in Caucasians. In the present series, nine SNPs in the PTPN22 gene were analyzed in 166 patients with AIH, 262 patients with PBC, and 322 healthy controls in the Japanese population using TaqMan assays. Although the functional rs3996649 and rs2476601 were non-polymorphic in all subject groups, the frequencies of the minor alleles at rs1217412, rs1217388, rs1217407, and rs2488458 were significantly decreased in AIH patients as compared with controls (all Pc < 0.05). There were no significant relationships with PTPN22 SNPs in PBC patients. Interestingly, the AAGTCCC haplotype was significantly associated with resistance to both AIH (odds ratio [OR] = 0.58, P = 0.0067) and PBC (OR = 0.58, P = 0.0048). SNPs in the PTPN22 gene may therefore play key roles in the genetic resistance to autoimmune liver disease in the Japanese.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27406031 PMCID: PMC4942688 DOI: 10.1038/srep29770
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Allelic Association Tests of Seven Genotyped SNPs in PTPN22.
| SNP | Position on Chr. 13 (Build 37.p13) | Gene location | Alleles (1 > 2) | Minor allele frequency, % | Controls vs. AIH | Controls vs. PBC | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls(n = 322) | AIH(n = 166) | PBC(n = 262) | OR (95% CI) | ||||||||
| rs1217412 | 113814589 | 3′UTR | G>A | 42.4 | 33.4 | 42.6 | 0.0066 | 0.68 (0.52–0.90) | 0.954 | >1.0 | |
| rs1217388 | 113821854 | intron | G>A | 42.4 | 33.4 | 42.6 | 0.0066 | 0.68 (0.52–0.90) | 0.954 | >1.0 | |
| rs1217407 | 113851126 | intron | A>G | 42.4 | 33.2 | 42.6 | 0.0066 | 0.68 (0.52–0.90) | 0.954 | >1.0 | |
| rs3765598 | 113851841 | intron | C>T | 21.6 | 15.1 | 16.4 | 0.0145 | 0.087 | 0.64 (0.45–0.92) | 0.026 | 0.18 |
| rs2488458 | 113863829 | intron | T>C | 42.6 | 33.4 | 42.6 | 0.0066 | 0.68 (0.52–0.90) | 0.954 | >1.0 | |
| rs3789612 | 113871486 | intron | C>T | 12.4 | 7.8 | 5.7 | 0.0400 | 0.24 | 0.60 (0.37–0.98) | 0.065 | 0.46 |
| rs2488457 | 113872746 | 5′ near gene | G>C | 42.2 | 33.4 | 38.2 | 0.0076 | 0.053 | 0.69 (0.52–0.91) | 0.159 | >1.0 |
1, major allele; 2, minor allele; OR, odds ratio; CI, confidence interval.
Genotype Distribution of PTPN22 Gene Polymorphisms in Patients with AIH or PBC and Healthy Controls.
| SNP | Alleles | Genotype | Genotype frequency,% | Model* | Controls vs. AIH | Controls vs. PBC | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (1>2) | Controls | AIH | PBC | OR (95% CI) | OR (95% CI) | |||||||
| (n = 322) | (n = 166) | (n = 262) | ||||||||||
| rs1217412 | G>A | AA/AG/GG | 15.2/54.4/30.4 | 10.2/46.4/43.4 | 17.9/49.2/32.8 | Dominant | 0.0048 | 0.57 (0.39–0.84) | 0.54 | >1.0 | ||
| (AA+AG vs.GG) | ||||||||||||
| rs1217388 | G>A | AA/AG/GG | 15.2/54.4/30.4 | 10.2/46.4/43.4 | 17.9/49.2/32.8 | Dominant | 0.0048 | 0.57 (0.39–0.84) | 0.54 | >1.0 | ||
| (AA+AG vs.GG) | ||||||||||||
| rs1217407 | A>G | GG/GA/AA | 15.2/54.4/30.4 | 10.2/46.4/43.4 | 17.9/49.2/32.8 | Dominant | 0.0048 | 0.57 (0.39–0.84) | 0.54 | >1.0 | ||
| (GG+GA vs. AA) | ||||||||||||
| rs3765598 | C>T | TT/TC/CC | 3.1/37.0/59.9 | 1.8/26.5/71.7 | 3.0/26.7/70.2 | Dominant | 0.0097 | 0.068 | 0.59 (0.39–0.89) | 0.0095 | 0.067 | 0.63 (0.45–0.90) |
| (TT+TC vs. CC) | ||||||||||||
| rs2488458 | T>C | CC/CT/TT | 15.2/54.4/30.4 | 10.2/46.4/43.4 | 17.9/49.2/32.8 | Dominant | 0.0048 | 0.57 (0.39–0.84) | 0.54 | >1.0 | ||
| (CC+CT vs. CC) | ||||||||||||
| rs3789612 | C>T | TT/TC/CC | 0.6/15.8/83.5 | 0.0/15.7/84.3 | 1.1/9.2/89.7 | Dominant | 0.82 | >0.2 | 0.03 | 0.21 | 0.58 (0.36–0.96) | |
| (TT+TC vs. CC) | ||||||||||||
| rs2488457 | G>C | CC/CG/GG | 14.9/54.7/30.4 | 9.6/47.6/42.8 | 13.4/49.6/37.0 | Dominant | 0.007 | 0.59 (0.40–0.86) | 0.094 | 0.66 | ||
| (CC+CG vs. CC) | ||||||||||||
1, major allele; 2, minor allele; OR, odds ratio; CI, confidence interval.
* The model with the smallest Akaike’s information criterion value was defined as the most appropriate model for each SNP.
Pairwise LD of Seven SNPs in PTPN22 Among 488 Patients with AIH and Healthy Controls.
| rs1217412 | rs1217388 | rs1217407 | rs3765598 | rs2488458 | rs3789612 | rs2488457 | |
|---|---|---|---|---|---|---|---|
| rs1217412 | — | 1.000 | 1.000 | 0.989 | 1.000 | 0.933 | 0.974 |
| 1.000 | 1.000 | 0.361 | 1.000 | 0.051 | 0.945 | ||
| rs1217388 | — | 1.000 | 0.989 | 1.000 | 0.933 | 0.974 | |
| 1.000 | 0.362 | 1.000 | 0.051 | 0.945 | |||
| rs1217407 | — | 0.989 | 1.000 | 0.933 | 0.974 | ||
| 0.361 | 1.000 | 0.050 | 0.945 | ||||
| rs3765598 | — | 0.989 | 1.000 | 0.944 | |||
| 0.361 | 1.000 | 0.331 | |||||
| rs2488458 | — | 0.933 | 0.974 | ||||
| 0.050 | 0.945 | ||||||
| rs3789612 | — | 1.000 | |||||
| 0.021 | |||||||
| rs2488457 | — |
The degree of LD is shown as a measure of D’ (upper) and r2 (lower) in each column.
Estimated Haplotype Frequencies of PTPN22 Gene Polymorphisms in Patients with AIH or PBC and Healthy Controls.
| rs1217412 | rs1217388 | rs1217407 | rs3765598 | rs2488458 | rs3789612 | rs2488457 | Frequency, % | Controls vs. AIH | Controls vs. PBC | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls(2n = 644) | AIH(2n = 332) | PBC(2n = 524) | OR (95% CI) | OR (95% CI) | ||||||||||
| 1 | G | G | A | C | T | C | G | 48.7 | 58.4 | 52.3 | 1.00 | 1.00 | ||
| 2 | A | A | G | C | C | C | C | 21.0 | 18.4 | 24.8 | 0.059 | 0.70(0.48–1.01) | 0.74 | 1.05(0.78–1.41) |
| 3 | A | A | G | T | C | C | C | 20.1 | 14.8 | 12.5 | 0.58(0.39–0.86) | 0.58(0.40–0.85) | ||
| 4 | G | G | A | C | T | T | G | 7.9 | 7.8 | 4.3 | 0.37 | 0.79(0.47–1.33) | 0.062 | 0.59(0.33–1.03) |
Abbreviations: OR, odds ratio; CI, confidence interval.
Figure 1Alignments of Bases (A) and Amino Acids (B) of Exon 14 in PTPN22. SNPs in bold type are polymorphic. 1; rs554195846 (A/G: Thr/Thr), 2; rs138223016 (C/A: Ala/Ser), 3; rs765535869 (C/T: Arg/Arg), 4; rs759881801 (T/C: Ile/Met), 5; rs764275349 (G/A: Pro/Leu), 6; rs2476601 (G/T: Arg/Trp), 7; rs201811041 (C/T: Arg/Gln), 8; rs74163660 (C/G: Pro/Arg), 9; rs768160390 (A/G: Ire/Thr), 10; rs368086285 (C/T: Val/Met), 11; rs775140391 (A/G: Val/Ala), 12; rs569454620 (C/T: Ala/Thr).
Demographic and Clinical Characteristics of Patients with AIH or PBC.
| Characteristic | AIH (n = 166) | PBC (n = 262) |
|---|---|---|
| Median age, years (range) | 59 (22–87) | 58 (27–86) |
| Female, n (%) | 147 (89) | 234 (89) |
| Cirrhosis, n (%) | 18 (11) | 45 (17) |
| OLT, n (%) | 0 (0) | 12 (5) |
| Serum ANA-positive, n (%) | 159 (96) | 215 (82) |
| Serum AMA-positive, n (%) | 0 (0) | 238 (91) |
Abbreviations: AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; OLT, orthotopic liver transplantation; ANA, anti-nuclear antibody; AMA, anti-mitochondrial antibody.